The case for eliminating excessive worry as a requirement for generalized anxiety disorder: a cross-national investigation.
classification
diagnosis
epidemiology
generalized anxiety disorder
global mental health
worry
Journal
Psychological medicine
ISSN: 1469-8978
Titre abrégé: Psychol Med
Pays: England
ID NLM: 1254142
Informations de publication
Date de publication:
04 Oct 2024
04 Oct 2024
Historique:
medline:
4
10
2024
pubmed:
4
10
2024
entrez:
4
10
2024
Statut:
aheadofprint
Résumé
Around the world, people living in objectively difficult circumstances who experience symptoms of generalized anxiety disorder (GAD) do not qualify for a diagnosis because their worry is not 'excessive' relative to the context. We carried out the first large-scale, cross-national study to explore the implications of removing this excessiveness requirement. Data come from the World Health Organization World Mental Health Survey Initiative. A total of 133 614 adults from 12 surveys in Low- or Middle-Income Countries (LMICs) and 16 surveys in High-Income Countries (HICs) were assessed with the Composite International Diagnostic Interview. Non-excessive worriers meeting all other Removing the excessiveness requirement increases the global lifetime prevalence of GAD from 2.6% to 4.0%, with larger increases in LMICs than HICs. Non-excessive and excessive GAD cases worry about many of the same things, although non-excessive cases worry more about health/welfare of loved ones, and less about personal or non-specific concerns, than excessive cases. Non-excessive cases closely resemble excessive cases in socio-demographic characteristics, family history of GAD, and risk of temporally secondary comorbidity and suicidality. Although non-excessive cases are less severe on average, they report impairment comparable to excessive cases and often seek treatment for GAD symptoms. Individuals with non-excessive worry who meet all other
Sections du résumé
BACKGROUND
BACKGROUND
Around the world, people living in objectively difficult circumstances who experience symptoms of generalized anxiety disorder (GAD) do not qualify for a diagnosis because their worry is not 'excessive' relative to the context. We carried out the first large-scale, cross-national study to explore the implications of removing this excessiveness requirement.
METHODS
METHODS
Data come from the World Health Organization World Mental Health Survey Initiative. A total of 133 614 adults from 12 surveys in Low- or Middle-Income Countries (LMICs) and 16 surveys in High-Income Countries (HICs) were assessed with the Composite International Diagnostic Interview. Non-excessive worriers meeting all other
RESULTS
RESULTS
Removing the excessiveness requirement increases the global lifetime prevalence of GAD from 2.6% to 4.0%, with larger increases in LMICs than HICs. Non-excessive and excessive GAD cases worry about many of the same things, although non-excessive cases worry more about health/welfare of loved ones, and less about personal or non-specific concerns, than excessive cases. Non-excessive cases closely resemble excessive cases in socio-demographic characteristics, family history of GAD, and risk of temporally secondary comorbidity and suicidality. Although non-excessive cases are less severe on average, they report impairment comparable to excessive cases and often seek treatment for GAD symptoms.
CONCLUSIONS
CONCLUSIONS
Individuals with non-excessive worry who meet all other
Identifiants
pubmed: 39364896
doi: 10.1017/S003329172400182X
pii: S003329172400182X
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
1-12Subventions
Organisme : U.S. Public Health Service
ID : R13-MH066849; R01-MH069864; R01 DA016558
Organisme : U.S. Department of Defense
Organisme : Generalitat de Catalunya
ID : 2017 SGR 452; 2014 SGR 748
Organisme : FIC NIH HHS
ID : FIRCA R03-TW006481
Pays : United States
Organisme : John D. and Catherine T. MacArthur Foundation
Organisme : European Commission
ID : QLG5-1999-01042; SANCO 2004123; EAHC 20081308
Organisme : EEA Grants
Organisme : Eli Lilly and Company
Organisme : Robert Wood Johnson Foundation
ID : 044708
Organisme : Ministerio de Ciencia y Tecnología
ID : SAF 2000-158-CE
Organisme : U.S. Department of Veterans Affairs
Organisme : National Insurance Institute of Israel
Organisme : GlaxoSmithKline
Organisme : Pan American Health Organization
Organisme : Bristol-Myers Squibb
Organisme : Fundación para la Formación e Investigación Sanitarias de la Región de Murcia
Organisme : SAMHSA HHS
Pays : United States
Organisme : Department of Health and Aged Care, Australian Government
Organisme : Pfizer Foundation
Organisme : John W. Alden Trust
Organisme : Fundação Calouste Gulbenkian
Organisme : Ministerio de Salud de la Nación
ID : 2002-17270/13-5
Organisme : Fundação Champalimaud
Organisme : Ortho-McNeil Pharmaceutical
Organisme : Instituto Nacional de Psiquiatría Ramón de la Fuente Muñiz
ID : INPRFMDIES 4280